Clinical trials
Intracranial Aneurysm trials in China with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
34 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2010 | 1 |
| 2014 | 1 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 2 |
| 2021 | 2 |
| 2022 | 3 |
| 2023 | 12 |
| 2024 | 4 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 18 |
| Completed | 10 |
| Recruiting | 6 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| MicroPort NeuroTech Co., Ltd. | 6 |
| Beijing Tiantan Hospital | 4 |
| Ton-Bridge Medical Tech. Co., Ltd | 4 |
| The First Affiliated Hospital with Nanjing Medical University | 3 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 2 |
| Shanghai Wallaby Medical Technologies Co.,Inc. | 2 |
| Sinomed Neurovita Technology Inc. | 2 |
| Zhihong LU | 2 |
| liuxingju | 2 |
| General Hospital of Ningxia Medical University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Intracranial Aneurysm | 34 |
| Aneurysm | 3 |
| Brain Diseases | 3 |
| Cardiovascular Diseases | 2 |
| Arteriovenous Malformations | 1 |
| Carotid-Cavernous Sinus Fistula | 1 |
| Intracranial Arteriosclerosis | 1 |
| Ischemic Stroke | 1 |
| Subarachnoid Hemorrhage | 1 |
| Vasospasm, Intracranial | 1 |
Trials
Showing 1 to 25 of 34. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.